# Comparative, Multicenter Study in Subjects with Rheumatoid Arthritis, ALVOFLEX

> **NCT05842213** · PHASE3 · COMPLETED · sponsor: **Alvotech Swiss AG** · enrollment: 502 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** AVT05 (proposed biosimilar to golimumab)
- **BIOLOGICAL:** Simponi (Golimumab)

## Key facts

- **NCT ID:** NCT05842213
- **Lead sponsor:** Alvotech Swiss AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-30
- **Primary completion:** 2024-03-04
- **Final completion:** 2024-09-24
- **Target enrollment:** 502 (ACTUAL)
- **Last updated:** 2024-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05842213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05842213, "Comparative, Multicenter Study in Subjects with Rheumatoid Arthritis, ALVOFLEX". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05842213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*